GLSI Greenwich LifeSciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1799788 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-27.9%
TTM EPS YoY-14.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-107,371.7%
ROA-481.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets129.6%
Debt / equity—
Current ratio0.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.55x
Accruals ratio-217.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $17.22M | $15.48M |
| SG&A expense | $2.23M | $2.16M |
| Operating income | -$19.45M | -$17.64M |
| Net income | -$19.36M | -$17.41M |
| EPS (basic) | -1.43 | -1.34 |
| EPS (diluted) | -1.43 | -1.34 |
| Weighted avg. shares (diluted) | 13.53M | 13.01M |
| Balance sheet | ||
| Cash & equivalents | $6.18M | $4.09M |
| Current assets | $6.18M | $4.09M |
| Intangibles | — | $1,779 |
| Total assets | $6.18M | $4.09M |
| Current liabilities | $5.82M | $3.19M |
| Total liabilities | $5.82M | $3.19M |
| Shareholders' equity | $353,217 | $908,626 |
| Shares outstanding | 14.30M | 13.15M |
| Cash flow statement | ||
| Operating cash flow | -$9.91M | -$7.27M |
| Financing cash flow | $12.00M | $4.37M |
| Stock-based compensation | $6.80M | $7.25M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.